NCT03899805 2025-08-28A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue SarcomasDana-Farber Cancer InstitutePhase 2 Completed57 enrolled 14 charts
NCT04099277 2021-08-31A Study of LY3435151 in Participants With Solid TumorsEli Lilly and CompanyPhase 1 Terminated2 enrolled 8 charts